Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 161

1.

Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.

Yang L, Kong Y, Ren H, Li M, Wei CJ, Shi E, Jin WN, Hao J, Vandenbark AA, Offner H.

Neurochem Int. 2017 Jul;107:148-155. doi: 10.1016/j.neuint.2016.11.007. Epub 2016 Nov 21.

2.

CD74 and intratumoral immune response in breast cancer.

Wang ZQ, Milne K, Webb JR, Watson PH.

Oncotarget. 2017 Feb 21;8(8):12664-12674. doi: 10.18632/oncotarget.8610.

3.

The multifaceted roles of the invariant chain CD74--More than just a chaperone.

Schröder B.

Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1269-81. doi: 10.1016/j.bbamcr.2016.03.026. Epub 2016 Mar 28. Review.

4.

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL Jr, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA.

Clin Cancer Res. 2016 Jun 15;22(12):3016-24. doi: 10.1158/1078-0432.CCR-15-2226. Epub 2016 Jan 18.

5.

CD74 expression and its therapeutic potential in thyroid carcinoma.

Cheng SP, Liu CL, Chen MJ, Chien MN, Leung CH, Lin CH, Hsu YC, Lee JJ.

Endocr Relat Cancer. 2015 Apr;22(2):179-90. doi: 10.1530/ERC-14-0269. Epub 2015 Jan 19.

PMID:
25600560
6.

MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas.

Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke H, Reiß S, Pennartz S, Winkelmann R, Senft C, Plate KH, Wischhusen J, Stenzel W, Harter PN, Mittelbronn M.

Brain Pathol. 2015 Jul;25(4):491-504. doi: 10.1111/bpa.12194. Epub 2014 Nov 20.

PMID:
25175718
7.

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25.

PMID:
24731748
8.

Involvement of CD74 in head and neck squamous cell carcinomas.

Kindt N, Lechien JR, Nonclercq D, Laurent G, Saussez S.

J Cancer Res Clin Oncol. 2014 Jun;140(6):937-47. doi: 10.1007/s00432-014-1648-9. Epub 2014 Mar 25.

PMID:
24663824
9.

The invariant chain p35 isoform promotes formation of nonameric complexes with MHC II molecules.

Cloutier M, Gauthier C, Fortin JS, Thibodeau J.

Immunol Cell Biol. 2014 Jul;92(6):553-6. doi: 10.1038/icb.2014.17. Epub 2014 Mar 18.

PMID:
24638068
10.

CD74: a new prognostic factor for patients with malignant pleural mesothelioma.

Otterstrom C, Soltermann A, Opitz I, Felley-Bosco E, Weder W, Stahel RA, Triponez F, Robert JH, Serre-Beinier V.

Br J Cancer. 2014 Apr 15;110(8):2040-6. doi: 10.1038/bjc.2014.117. Epub 2014 Mar 4.

11.

Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.

Tan X, Wu Q, Cai Y, Zhao X, Wang S, Gao Z, Yang Y, Li X, Qian J, Wang J, Su B, Chen H, Han B, Jiang G, Lu D.

Clin Lung Cancer. 2014 Jan;15(1):67-78.e12. doi: 10.1016/j.cllc.2013.08.006. Epub 2013 Nov 9.

PMID:
24220096
12.

Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.

Hollmig ST, Rieger KE, Henderson MT, West RB, Sundram UN.

Am J Dermatopathol. 2013 Apr;35(2):176-9. doi: 10.1097/DAD.0b013e318265fb9e.

PMID:
23000905
13.

Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Chornoguz O, Gapeev A, O'Neill MC, Ostrand-Rosenberg S.

Mol Cell Proteomics. 2012 Nov;11(11):1457-67. doi: 10.1074/mcp.M112.019232. Epub 2012 Aug 31.

14.

CD74: a potential novel target for triple-negative breast cancer.

Tian B, Zhang Y, Li N, Liu X, Dong J.

Tumour Biol. 2012 Dec;33(6):2273-7. doi: 10.1007/s13277-012-0489-x. Epub 2012 Aug 31.

PMID:
22935920
15.

CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.

Choi JW, Kim Y, Lee JH, Kim YS.

Int J Urol. 2013 Feb;20(2):251-5. doi: 10.1111/j.1442-2042.2012.03128.x. Epub 2012 Aug 21.

16.

Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.

Zuo J, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, Taylor GS, Rowe M.

PLoS Pathog. 2011 Dec;7(12):e1002455. doi: 10.1371/journal.ppat.1002455. Epub 2011 Dec 22.

17.

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA.

Blood. 2011 Dec 22;118(26):6893-903. doi: 10.1182/blood-2011-06-363879. Epub 2011 Oct 31.

18.

HIV-mediated up-regulation of invariant chain (CD74) correlates with generalized immune activation in HIV+ subjects.

Ghiglione Y, Rodríguez AM, De Candia C, Carobene M, Benaroch P, Schindler M, Salomón H, Turk G.

Virus Res. 2012 Jan;163(1):380-4. doi: 10.1016/j.virusres.2011.09.011. Epub 2011 Sep 16.

PMID:
21945129
19.

Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

Gold DV, Stein R, Burton J, Goldenberg DM.

Int J Clin Exp Pathol. 2010 Nov 23;4(1):1-12.

20.

Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.

Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C, Sarkaria JN.

J Neurooncol. 2010 Nov;100(2):177-86. doi: 10.1007/s11060-010-0186-9. Epub 2010 May 5.

Supplemental Content

Support Center